Addressing Gaps in Access to Reproductive Health Supplies: the role of generics medicine manufacturers

Anne-Charlotte Douard, Government engagement and Policy Officer
Access to Medicine Foundation
October 20, 2023
90%
About the Access to Medicine Foundation

• The Foundation mobilises leading healthcare companies to improve access to their essential medicines in low- and middle-income countries (LMICs).

• The Foundation is an independent non-profit organisation. Determined to maintain the impartiality of its changemaking research, it does not accept funding from the pharmaceutical industry or any healthcare company.

Funded by:

[Logos of Ministry of Foreign Affairs, Helmsley Charitable Trust, Axa Investment Managers]
Portfolios

- Hypertensive disorders of pregnancy
- Maternal hemorrhage
- Contraceptive methods
- HIV/AIDS
- Oncology (cervical, ovarian and breast cancer)
At least one of the five companies has filed or successfully registered a product selected for analysis.

At least one of the five companies has previously filed or successfully registered any product from across their portfolios, but none of the products selected for analysis have been filed for registration.

None of the five companies have filed any products for registration, across their entire portfolios.

Not in scope.
The majority of the products in scope are covered by an access strategy.

What types of access strategies are companies implementing?

- Patient Assistance Programme: 2
- Donations: 2
- Public Private Partnership: 2
- Tenders: 22
- Pricing strategies and contract agreements: 38

- Number of products not covered by any access strategy
- Number of products covered by an access strategy in at least one country in scope
Diseases targeted by adaptive R&D projects in scope

- Type 2 diabetes: 3 projects
- HIV: 2 projects
- Cryptococcal meningitis: 1 project
- Tuberculosis: 2 projects
- Lower respiratory infections: 1 project
Opportunities for the 5 companies in scope to improve

- Opportunities in companies' portfolios
- Opportunities in registrations, especially LICs and high burden countries
- Opportunities in comprehensive access strategies and access planning
- Need to consider more local manufacturing
- Continue to engage in adaptive R&D inclusive of LMICs
Thank you!

Anne-Charlotte Douard
acdouard@accesstomedicinefoundation.org
www.accesstomedicinefoundation.org

Spotlight on the generics industry: New analysis looks at access efforts of 5 major companies